Bioinformation Therapy for Liver Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 2, 2017

Primary Completion Date

September 2, 2018

Study Completion Date

September 2, 2018

Conditions
Liver, Cancer of, Non-Resectable
Interventions
DEVICE

Cancer ablation

Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

DRUG

Life information rehabilitation therapy

Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Trial Locations (1)

510665

Fuda cancer institute of Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shengxin Biotechnology Institute, Beijing

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT03239158 - Bioinformation Therapy for Liver Cancer | Biotech Hunter | Biotech Hunter